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Psoriasis is a very common chronic skin disease, affecting 2–3% of the world’s population or more than 125
million individuals worldwide. The characteristic lesion of psoriasis is due to rapid proliferation and shortened
transition of keratinocytes through the epidermis. Proinflammatory white blood cells (WBCs) migrate into the
psoriatic plaques, and the pathogenic cytokine environment causes the changes in keratinocyte proliferation
and differentiation. Enhanced migration of WBCs is due to the upregulation and activation of adhesion
molecules such as leukocyte function antigen-1 (LFA-1), which binds intercellular adhesion molecule-1 (ICAM-1)
on endothelial cells. Targeting LFA-1 and preventing interaction with ICAM-1 has proven an effective strategy for
treating psoriasis. We show here that a natural leukocyte-targeting bacterial protein (leukotoxin (LtxA)) that
binds LFA-1 can inhibit proliferation of activated WBCs from psoriasis patients and demonstrates significant
therapeutic efficacy in a psoriasis xenograft transplantation model. In ex vivo studies, LtxA preferentially
targeted proinflammatory WBC subtypes, including activated CD25þ Tcells and CD14þCD16þ monocytes. LFA-
1 has been shown to have a significant role in the pathogenesis of numerous autoimmune and inflammatory
diseases, and we propose that LtxA may be a highly effective agent for treating these diseases.
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INTRODUCTION
Psoriasis is one of the most prevalent inflammatory skin
diseases, afflicting 2–3% of the population or 125 million
people worldwide (Nestle et al., 2009; Valdimarsson et al.,
2009). It is well established that psoriasis is a lifelong
and complex disease with a hereditary basis. The disease
is fundamentally an inflammatory skin condition that
results from a dysregulated immune response, leading to
the activation of immune cells in the skin and resulting in
an abnormal proliferation and differentiation of epidermal
keratinocytes. At the skin surface, differentiated keratino-
cytes manifest as elevated and scaly lesions that vary in size
fromo1 cm to several centimeters. The thickened epidermis,
expanded dermal vascular compartment, and infiltrate of
immunocompetent cells in both the dermis and the epidermis
account for the characteristic psoriatic lesions.
Studies have shown that the white blood cells (WBCs)
involved in psoriasis have an upregulation and activation of
leukocyte function antigen-1 (LFA-1) (McGregor et al., 1992;
de Boer et al., 1994). LFA-1 is a b2-integrin on the surface of
WBCs composed of CD11a and CD18, and involved in immune
cell migration and signaling (Kinashi, 2005). LFA-1 is also
involved in cellular activation and stimulation through inter-
action with its natural ligand, intercellular adhesion molecule-1
(ICAM-1) (Abraham et al., 1999; Camacho et al., 2001;
Chirathaworn et al., 2002; Kandula and Abraham, 2004). LFA-1
can exist in multiple states, including an activated form and
an inactive form (Hogg et al., 1993; Hogg et al., 2004). LFA-1 in
the activated form binds ICAM-1 on endothelial cells and leads
to extravasation of WBCs into tissue. Efalizumab, a recombinant
monoclonal antibody that binds to the CD11a subunit of LFA-1,
was approved for clinical use in patients with psoriasis but
was later withdrawn from the market because of increased risk
of viral infection of the central nervous system (progressive
multifocal leukoencephalopathy; Sterry et al., 2009).
Leukotoxin (LtxA) is aB113-kDa protein produced by the
Gram-negative oral bacterium Aggregatibacter actinomyce-
temcomitans (reviewed recently in Kachlany (2010)) and
binds specifically to LFA-1 (Lally et al., 1997). After binding
LFA-1, LtxA kills WBCs of humans and old-world primates by
inducing apoptosis at low doses and necrosis at high doses
(Korostoff et al., 1998; Korostoff et al., 2000). Cells that lack
LFA-1 are resistant to killing by LtxA, and we recently showed
that LtxA preferentially targets cells with high amounts of
activated LFA-1 (Kachlany et al., 2010). Thus, LtxA kills only
a subset of WBCs, without affecting other cells or organs in
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the body. Because of the high degree of specificity of the
native protein, we have been investigating the potential
therapeutic utility of LtxA for targeting WBC diseases.
In preclinical animal studies, LtxA was shown to be highly
effective in treating leukemia, and when injected in a non-
human primate, LtxA was active, specific, and well tolerated
(Kachlany et al., 2010). After administration of LtxA to the non-
human primate, we observed partial (B50%) depletion of only
WBCs and the drop was transient (Kachlany et al., 2010),
suggesting that prolonged immunosuppression would not occur.
There is no cure for psoriasis, but current treatments
for mild-to-moderate psoriasis include topical therapy
and phototherapy. Systemic administration of retinoids,
methotrexate, and cyclosporine has mainly been reserved
for moderate and severe cases because of associated risks
and known adverse reactions (Kunz, 2009; Poulin et al.,
2009). Over the last decade, targeted therapy in the form of
biologics has shown many advantages over the ‘traditional
systemics’ and exhibit fewer side effects. In this report, we
tested LtxA against activated WBCs from psoriasis patients
and in a humanized animal model for psoriasis.
RESULTS
Effect of LtxA and efalizumab on proliferation of activated
PMBCs from psoriasis patients
To determine the activity of LtxA on activated peripheral
blood mononuclear cells (PBMCs) from psoriasis patients,
we isolated PBMCs from 10 donors with severe plaque
psoriasis (3 women and 7 men, age 29–63 years (average
48±13 years)). PBMCs were isolated from blood samples
by centrifugation over a lymphoprep density gradient
(Sigma-Aldrich, Broenby, Denmark) and then activated
using staphylococcal enterotoxin B (Sigma-Aldrich) and
treated with dilutions of LtxA or efalizumab. We found that
both LtxA and efalizumab inhibited proliferation of the
activated PBMCs from psoriasis patients, but the effective
doses of LtxA were B16,000 times lower than those of
efalizumab (Figure 1).
Establishment of the psoriasis xenograft transplantation model
We wished to determine whether LtxA has the ability to
alleviate symptoms of psoriasis in vivo. For these studies, we
used the established humanized mouse model where human
psoriatic plaques are transplanted onto severe combined
immunodeficient mice (Dam et al., 1999; Villadsen et al.,
2003; Villadsen et al., 2007; Stenderup et al., 2009; Jakobsen
et al., 2009; Rosada et al., 2010). Skin biopsies from two
patients with severe plaque-type psoriasis were grafted onto
mice and LtxA (0.5mgkg1 (4.4nmol kg1)), efalizumab
(6mgkg1 (40nmol kg1)), or vehicle (tris buffer/NaCl) was
administered once daily by intraperitoneal injection for 3 weeks.
Over the 3-week period, mice treated with LtxA did not show
any adverse physiological changes, and their bodyweight
increased similarly to the vehicle-treated mice (data not shown).
Clinical assessment of psoriatic plaques
Semiquantitative clinical psoriasis scores were recorded
twice weekly throughout the study. Assessment was based
on a scale of 0–3, where 3 represents full psoriasis and
0 represents lack of disease. LtxA significantly decreased
the semiquantitative clinical psoriasis score (Po0.001) after
3 weeks of treatment (Figure 2a). Efalizumab (at nine times
higher concentration (mol kg1) than LtxA) also decreased the
clinical psoriasis score (P¼0.094) after 3 weeks, however,
not to a significant degree (Figure 2a).
Epidermal thickness was measured on hematoxylin and
eosin-stained paraffin-embedded sections after 3 weeks of
treatment. LtxA (45%; P¼0.002) and efalizumab (35%;
P¼0.024) significantly decreased the epidermal thickness
(Figure 2b and c).
LtxA 45% Inhibition
4 3.5
Efalizumab
3.0
2.5
2.0
1.5
1.0
0.5
0.0
3
2
1
0
R
el
at
ive
 p
ro
life
ra
tio
n
** **
**
**
**
**
SE
B
SE
B
SE
B+
Efa
 bu
ffe
r
SE
B+
Efa
 (16
 µM
)
SE
B+
Efa
 (33
 µM
)
SE
B+
Efa
 (67
 µM
)
SE
B+
Ltx
A b
uff
er
SE
B+
Ltx
A (1
 nM
)
SE
B+
Ltx
A (2
 nM
)
SE
B+
Ltx
A (4
 nM
)
74% Inhibition
Figure 1. Effect on proliferation of white blood cells from psoriasis patients. Peripheral blood mononuclear cells were isolated from 10 psoriasis patients,
activated with staphylococcal enterotoxin B (SEB), and treated with different doses of leukotoxin (LtxA) or efalizumab (Efa) for 72 hours. Proliferation was
measured using an ATP-based assay comparing activated cultures with non-activated.
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Psoriatic skin is characterized by an increased infiltration
of lymphocytes compared with healthy skin. To determine
the pathological effect of LtxA therapy, we determined
the lymphocyte score. The score is an assessment of the
degree of lymphocytic infiltrate present both in the dermal
and the epidermal compartment. LtxA (P¼ 0.005) and
efalizumab (P¼0.008) both significantly decreased the
degree of lymphocytic infiltration after 3 weeks of treatment
(Figure 2d). Evaluation of skin biopsies was performed
randomly in a blinded manner.
Sensitivity of activated T cells to LtxA
We previously showed that a Jurkat T-cell line expressing a
constitutively activated form of LFA-1 was B10 times more
sensitive to LtxA than parental wild-type cells (Kachlany
et al., 2010). We wished to determine whether primary
T cells that are naturally activated are also more susceptible
to LtxA-mediated apoptosis. We treated human PBMCs with
LtxA and then determined the levels of killing of activated
CD4þCD25þ cells and resting CD4þCD25 cells. We
found that activated CD25þ T cells from three different
donors were consistently more sensitive to LtxA than resting
cells (CD4þCD25; Figure 3a). The percentage of apoptosis
of CD4þCD25þ cells ranged from 21 to 190% greater than
CD4þCD25 cells.
Effect of LtxA on CD16þ monocytes
In addition to lymphocytes, monocytes/macrophages that
migrate from circulation into the tissue have a critical role in
the pathogenesis of psoriasis (van den Oord and de
Wolf-Peeters, 1994; Nickoloff, 2000; Vestergaard et al.,
2004). Specifically, CD16þ proinflammatory monocytes are
increased in patients with autoimmune disease and inflam-
mation (Fingerle et al., 1993; Baeten et al., 2000; Todd et al.,
2007; Ziegler-Heitbrock, 2007; Chiu et al., 2010). To
determine whether LtxA also has an effect on proinflamma-
tory monocytes, we tested the activity of LtxA on peripheral
blood, gating for CD14þCD16þ monocytes. We found that
primary CD16þ monocytes were highly sensitive to LtxA in a
dose-dependent manner, as determined by Annexin V
staining and flow cytometry (Figure 3b).
DISCUSSION
In this paper, we show that a natural bacterial protein with
specificity for WBCs is highly effective in inhibiting
proliferation of activated WBCs from psoriasis patients and
promoting resolution of psoriasis in a psoriasis xenograft
transplantation model. The receptor for LtxA, LFA-1, has been
previously validated as an effective target for treatment of
psoriasis in both animal models (Zeigler et al., 2001) and
humans (Jullien et al., 2004; Harper et al., 2008).
Lymphocytes, and specifically T cells, are believed to be
the critical cell type for initiating and perpetuating psoriasis
(Wrone-Smith and Nickoloff, 1996; Gilhar et al., 1997). We
found that activated primary CD4 T cells are more sensitive to
LtxA than resting cells using CD25 as a marker for T-cell
activation. The difference in sensitivities between the three
donors that we observed likely represents the natural
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Figure 2. Effect of treatment on human xenograft transplants. (a) Clinical psoriasis assessment. Psoriatic plaque transplants on severe combined
immunodeficient mice were evaluated twice weekly using a scale of 0–3. Treatment was vehicle (neg), leukotoxin (LtxA), or efalizumab (Efa) daily for 3 weeks.
(b) Effect of treatment on epidermal thickness of psoriatic plaques. After 3 weeks of treatment, epidermal sections of transplants were stained with hematoxylin
and eosin (H&E) and the thickness (mm) was determined. (c) Representative histology of H&E-stained paraffin-embedded sections. Bar¼200 mm. (d) Assessment
of lymphocyte infiltration in transplants. H&E-stained epidermal sections were evaluated for the histological presence of lymphocytes after 3 weeks of treatment.
A score of 4 represents maximum lymphocyte infiltration and 0 represents baseline infiltration. Shown is mean±SEM. Efa, efadizumab; neg, negative.
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variation of activation states of human clinical samples.
Furthermore, it is possible that a T cell is CD25 but
expresses an activated form of LFA-1 and the inverse. These
results suggest that the activated WBCs responsible for
disease in psoriasis patients would be preferential targets for
LtxA. It is important to point out that WBCs lacking LFA-1 are
not affected by LtxA (Lally et al., 1997; Kachlany et al., 2010).
In addition to lymphocytes, macrophages are also implicated
in disease. Presentation of antigen to T cells by macrophages
can trigger a Th1-type cellular immune reaction that leads to
psoriatic lesions (Baker et al., 2001; Baker et al., 2006), and
local elimination of macrophages has led to resolution of
cutaneous inflammation (Thepen et al., 2000). CD16þ
monocytes constitute the proinflammatory subset of mono-
cytes and are increased in patients with psoriasis and
psoriatic arthritis (Chiu et al., 2010), rheumatoid arthritis
(Baeten et al., 2000), and other inflammatory conditions
(Ziegler-Heitbrock, 2007). These cells have been shown to
produce higher amounts of tumor necrosis factor-a, can
differentiate into dendritic cells, and possess proinflammatory
properties that contribute to the pathogenesis of inflammatory
diseases (Strauss-Ayali et al., 2007). We show that CD16þ
monocytes were highly sensitive to LtxA, suggesting that
these cells could also be targeted during treatment.
Efalizumab is an anti-LFA-1 monoclonal antibody therapy
that was approved for use in psoriasis patients. As a
comparator, we have used efalizumab because it addresses
the same target as LtxA. The drug was recently removed from
the market because of the increased risk of progressive
multifocal leukoencephalopathy, a rare viral disease char-
acterized by inflammation of the brain, during extended use.
Although LtxA also targets LFA-1, there are important
pharmacological differences between LtxA and efalizumab.
First, LtxA is a naturally-occurring (non-engineered and non-
recombinant) protein produced by a bacterium that is present
in the oral cavity of a large percentage of the healthy
population (Leys et al., 1994; Lamell et al., 2000). Clinically,
efalizumab does not cause depletion of lymphocytes or other
WBCs, but inhibits T-cell activation in the lymph nodes and
binding of T cells to endothelial cells (Jullien et al., 2004). In
contrast, LtxA preferentially targets and depletes WBCs with
activated LFA-1. Because of this preference for WBCs
expressing activated LFA-1, most of the resting immune cells
would be spared after LtxA treatment. For example, when
administered intravenously to a Rhesus macaque, LtxA
caused transient depletion of WBCs (several hours), and the
levels never dropped below 50% (Kachlany et al., 2010). In
addition to T cells, LtxA targets other WBCs that are involved
in inflammatory disease, including proinflammatory mono-
cytes. Hence, we would expect for LtxA to be a highly potent
therapeutic agent because it acts on the multiple cell
types that are involved in the pathogenesis of psoriasis.
Indeed, we found here that LtxA was just as or more effective
as efalizumab in vivo, however, at a 9-fold lower dose.
Recently, Koszik et al. (Koszik et al., 2010) reported that
efalizumab induces a state hyporesponsiveness in T cells, and
this effect may explain why prolonged use of the drug can
lead to immunosuppression and increased risk of progressive
multifocal leukoencephalopathy. The different mechanisms
of action exhibited by these two LFA-1-targeting agents may
explain the difference in efficacy and doses required in the
models presented here.
In a similar study, the effect of inhibiting another integrin,
very late antigen-1 (VLA-1), was investigated in psoriasis
(Conrad et al., 2007). Like LFA-1, VLA-1 is a heterodimeric
integrin and is composed of CD94a and CD29. VLA-1 binds
to collagen IV of the basement membrane in skin, and only
when T cells have entered the epidermis, they express VLA-1.
Blocking of VLA-1 prevented the accumulation of epidermal
T cells and the development of psoriasis in the AGR psoriasis
xenograft transplantation model where transplanted non-
lesional skin from psoriasis patients spontaneously develops
into psoriasis (Conrad et al., 2007). This study further supports
our therapeutic strategy of affecting subgroups of activated
T cells by targeting WBC integrins.
Treatment with efalizumab results in an increase in circu-
lating WBCs presumably because the drug blocks migration
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Figure 3. Susceptibility of white blood cells to leukotoxin (LtxA).
(a) Effects of LtxA on activated T cells. Peripheral blood mononuclear cells
(PBMCs) from three different human donors were treated with LtxA
(40 ngml1) for 2 hours. Cells were stained with anti-CD4/CD25 antibodies
and Annexin V (indicating apoptosis) and analyzed using flow cytometry.
All samples were normalized to buffer treatment, and at least 20,000 cells
were analyzed per sample. The values of CD4þCD25 cells from donors
1 and 2 were slightly less than 1. (b) LtxA-induced apoptosis of
proinflammatory monocytes. PBMCs were treated with LtxA for 24 hours
and then stained with anti-CD14/CD16 antibodies and Annexin V, and
analyzed by flow cytometry. Data represent mean±SEM from three
independent donor samples. *Po0.05.
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of cells out of the blood (Jullien et al., 2004; Harper et al.,
2008). Interestingly, we observed that intravenous adminis-
tration of LtxA to a non-human primate resulted in an initial
drop in WBC counts, followed by an increase in circulating
WBCs within 24 hours (Kachlany et al., 2010). We attributed
this increase in WBC count to migration of cells from the
tissue and into circulation to replenish depleted cells;
however, we also believe that binding of LtxA at low doses
to LFA-1 may be blocking migration of WBCs out of the blood
and into the tissues, much like the effects of efalizumab. In
the mouse model presented here, LtxA most likely exerts its
anti-psoriasis effects by depleting the WBCs that are resident
in the grafted human tissue. In a psoriasis patient, although
systemic LtxA not only would target and deplete circulating
activated WBCs but also would prevent their migration into
the skin and subsequent inflammation and plaque formation.
Although LtxA may have the potential to stimulate an
immune response, in preliminary studies using Rhesus
monkeys and immunocompetent mice, we did not detect
neutralizing antibody against the protein (unpublished data).
Nonetheless, more extensive experiments are required to
fully determine the protein’s immunogenic potential in
humans.
In addition to psoriasis, LFA-1 has been shown to have a
significant role in the pathogenesis of other autoimmune and
inflammatory diseases. Patients with lupus have increased
expression of LFA-1 on T cells (Takasaki et al., 1999), and
mice deficient in LFA-1 showed increased survival and
reduced pathogenesis in a mouse model for lupus (Kevil
et al., 2004). Furthermore, treatment of mice with anti-LFA-1
monoclonal antibody alleviated symptoms of disease in
experimental murine lupus models (Connolly et al., 1994;
Kootstra et al., 1997). Watts et al. (2005) showed that LFA-1 is
critically important for induction of inflammatory arthritis in
mice and that blocking LFA-1 with monoclonal antibody
ameliorated disease. In patients with multiple sclerosis, LFA-1
is highly expressed on immune cells in the blood and central
nervous system (Lou et al., 1997; Elovaara et al., 2000), and
treatment with methylprednisolone reduces levels of LFA-1
on monocytes and lymphocytes in multiple sclerosis patients
(Elovaara et al., 1998). In ulcerative colitis and Crohn’s
disease, leukocytes in the intestinal tissue have increased
expression of LFA-1, which has a role in the migration of
WBCs from circulation toward the colonic epithelium (Vainer
et al., 2000; Bernstein et al., 2002). LFA-1 was also shown to
be involved in the pathogenesis of type I diabetes in both
humans and experimental animal models (Hasegawa et al.,
1994; Linn et al., 1994; Somoza et al., 1994; Mysliwiec et al.,
1999). Thus, LtxA may have significant therapeutic potential
for the treatment of psoriasis and numerous other auto-
immune and inflammatory diseases.
MATERIALS AND METHODS
LtxA purification
LtxA was purified from culture supernatants of A. actinomycetem-
comitans strain NJ4500, as previously described (Diaz et al., 2006).
Protein was lyophilized in sterile vials and stored at 80 1C
until used.
Isolation and treatment of PBMCs from psoriasis patients
PBMCs were obtained from 10 donors with severe plaque-type
psoriasis, 3 women and 7 men, age 29–63 years (48±13 years).
PBMCs were isolated from whole-blood samples by centrifugation
over a lymphoprep density gradient (density¼ 1.077±0.001 g cm3)
and viable cells counted. PBMCs were cultured in cell medium:
RPMI-1640 medium containing 10% heat-inactivated human serum
pool, and 1% penicillin/streptomycin/gentamycin, at 5% CO2,
371C, and 90% humidity. Cells were seeded at a concentration
of 1 106 cellsml1; 100ml (1 105 cells) was added to each well
of a 96-well-plate. Cells were activated with staphylococcal
enterotoxin B at a final concentration of 1.0 mgml1. Staphylo-
coccal enterotoxin B and test reagents were incubated for
72 hours. Proliferation was assessed by the CellTiter-Glo Viability
Assay Kit (Promega, Madison, WI). Proliferation was evaluated
as percent cell viability upon activation as compared with non-
activated cultures.
Psoriasis xenograft transplantation model
Keratome skin biopsies of lesional skin were obtained after informed
consent from two patients with severe plaque-type psoriasis. The
patients’ psoriasis was untreated for at least 1 month before the time
of skin removal. Keratome skin biopsies were cut into smaller pieces
before transplantation onto the back of anesthetized (subcutaneous
injection of Ketaminol (ketamine, 100mg kg1; Intervet, Skovlunde,
Denmark) and Narcoxyl (xylazine, 10mg kg1; Intervet)) SCID mice
(female, 6- to 8-week of age, M&B Taconic, Laven, Denmark). After
a healing period of 10 days, the animals were divided into separate
treatment groups. A total of 24 mice were used in the study. Animals
were allocated to two consecutive study series, each representing
skin grafts from one individual psoriasis patient (total of two patients,
12 mice for each series). Each series was subdivided into four
groups. One group in each series served as untreated control
(two mice), whereas the other groups were allocated to treatment
with LtxA (four mice), efalizumab (four mice), or LtxA vehicle
(two mice). LtxA (0.5mg kg1 (4.4 nmol kg1)), efalizumab
(6mg kg1 (40 nmol kg1)), and vehicle (tris buffer/NaCl) were
administered once daily by intraperitoneal injection for 3 weeks.
The LtxA dose was chosen based on a previous study where
LtxA in a concentration of 2mg kg1 was administered, with a
therapeutic effect in a mouse leukemia xenograft model
(Kachlany et al., 2010). The efalizumab dose was chosen based on
previous studies in the psoriasis xenograft transplantation model
where 6mg kg1 efalizumab or 10mg kg1 anti-ICAM-1 were
administered to mice, demonstrating a therapeutic effect
(Zeigler et al., 2001; Boehncke et al., 2005). Throughout the
study, untreated mice appeared identical to the vehicle-treated
mice, and so these animals were grouped together as the negative
control.
During treatment, human psoriatic skin grafts were clinically
assessed twice weekly and given a semiquantitative clinical psoriasis
score according to the clinical signs: scaliness, induration, and
erythema. The parameters were scored using the three-point scale:
0¼ complete lack of cutaneous involvement; 1¼ slight involvement;
2¼moderate involvement; and 3¼ severe involvement. On this
scale from 0 to 3, a maximal score of 3 represents severe scale,
induration, and erythema of the psoriatic xenografts. After 3 weeks
and after the final clinical assessment, the animals were killed, and
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4-mm size punch biopsies were taken centrally from each human
psoriatic skin graft. We assessed epidermal thickness and presence of
lymphocytes on five hematoxylin and eosin-stained sections from
paraffin-embedded punch biopsies. Epidermal thickness was
measured as the distance from stratum corneum to the deepest part
of the rete pegs. Lymphocytes were evaluated and given a score
in the range 0–4, where 0 denotes no psoriasis and 4 denotes full
psoriasis. All sections were blinded before evaluation, and sections
were evaluated randomly.
Statistical analyses
Results for Figure 1 are shown as mean±SD. Results for Figures 2
and 3 are shown as mean±SEM. The non-parametric Mann–Whit-
ney test was used to test for differences between treatment groups in
semiquantitative clinical psoriasis scores and lymphocyte scores.
Student’s t-test was used to test for no differences between treatment
groups for WBC proliferation, epidermal thickness, and monocyte
apoptosis. Observations made for different mice were assumed to
be independent of each other. All tests were two-sided, and P-values
o 0.05 were considered significant.
Isolation of PBMCs from healthy subjects
Human peripheral blood ‘leukocyte units’ from anonymous donors
were provided by the New York Blood Center. PBMCs were isolated
by ficoll density gradient centrifugation and resuspended in RPMI
1640 media containing 10% fetal bovine serum.
Treatment with leukotoxin and flow cytometry
Both activated and non-activated PBMCs (1 106 cellsml1) were
cultured in the presence of LtxA (0.4 –400 ngml1) or buffer for
2 hours at 37 1C. Surface markers for monocytes and activated
T cells were detected via flow cytometry by staining 1 106 cells
on ice with anti-human antibodies CD14 allophycocyanin,
CD16 PE-Cy5, CD4 PE, and CD25 PE-Cy5 (BioLegend, San Diego,
CA). For detection of apoptosis, cells were subsequently stained
with Annexin V fluorescein isothiocyanate or Annexin V Alexa
Fluor 647 (BioLegend), incubated on ice in the dark for 15minutes,
and resuspended in 1 Annexin V binding buffer according
to the manufacturer’s protocol. At least 20, 000 events in the
live gate were acquired on the LSR II using FACSDiva
Software 6.0 (BD Biosciences, Franklin Lakes, NJ). Data was
analyzed using either FACSDiva Software or FlowJo Software
(Tree Star, Ashland, OR).
Human and animal protocol approvals
Human psoriasis studies were approved by the Central Denmark
Region Committees on Biomedical Research. All patients consented
to graft donation in writing. The animal studies were carried out in
the Animal Facility of the University of Aarhus, with approval from
the Danish Experimental Animal Inspectorate. The protocol for use
of PBMCs from healthy subjects was approved by the University of
Medicine and Dentistry of New Jersey Institutional Review Board
(Newark, NJ). All human studies were performed in accordance with
the Declaration of Helsinki Principles.
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